TEVA Q3 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B+7.1% YoY

Gross Profit

$1.9B48.1% margin

Operating Income

$344M8.9% margin

Net Income

$69M1.8% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

-$144M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$42.1B

Total Liabilities

$34.6B

Stockholders' Equity

$6.9B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$3.6B	+7.1%
Gross Profit	$1.9B	$1.7B	+10.9%
Operating Income	$344M	$419M	-17.9%
Net Income	$69M	$56M	+23.2%

Revenue Segments

Product

$3.3B86%

Distribution Service

$377M10%

Product and Service, Other

$117M3%

License

$53M1%

Geographic Segments

North America Segment

$2.0B55%

Europe Segment

$1.1B32%

International Markets

$485M13%